Provided by Tiger Trade Technology Pte. Ltd.

Fortress Biotech

3.12
+0.03000.97%
Post-market: 3.150.0300+0.96%18:48 EDT
Volume:247.49K
Turnover:774.88K
Market Cap:96.84M
PE:-10.65
High:3.18
Open:3.05
Low:3.05
Close:3.09
52wk High:4.53
52wk Low:1.33
Shares:31.04M
Float Shares:23.51M
Volume Ratio:0.70
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2930
EPS(LYR):-2.6890
ROE:-205.29%
ROA:-34.25%
PB:1.73
PE(LYR):-1.16

Loading ...

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of Cutx-101 Nda Resubmission

THOMSON REUTERS
·
Dec 15, 2025

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (Dfd-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

THOMSON REUTERS
·
Dec 10, 2025

Avenue Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 06, 2025

Mustang Bio Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 04, 2025

Fortress Biotech Jumps in Volume Spike, Last up 3.7%

THOMSON REUTERS
·
Dec 04, 2025

BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

Reuters
·
Nov 17, 2025

Sentynl Resubmits CUTX-101 NDA to FDA for Menkes Disease Treatment

Reuters
·
Nov 17, 2025

Fortress Biotech Inc: on Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted the Nda for Cutx-101 to the FDA

THOMSON REUTERS
·
Nov 17, 2025

Fortress Biotech: Cyprium to Retain Ownership Over Any Prv Upon Nda Approval, to Receive Royalties & up to $129 Mln in Milestones

THOMSON REUTERS
·
Nov 17, 2025

Fortress Biotech’s Earnings Call Highlights EMROSI Success

TIPRANKS
·
Nov 15, 2025

Fortress Biotech: Q3 EPS $0.11

THOMSON REUTERS
·
Nov 14, 2025

Corrected-Fortress Biotech 9-Month Revenue USD 47.183 Million (Corrects Amount)

THOMSON REUTERS
·
Nov 14, 2025

Fortress Biotech 9M Net Income USD -27.518 Million

THOMSON REUTERS
·
Nov 14, 2025

Fortress Biotech: Q3 Revenue $17.6 Mln

THOMSON REUTERS
·
Nov 14, 2025

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
Nov 14, 2025

Axsome Therapeutics Acquires Baergic Bio and Global Rights to BAER-101 from Avenue Therapeutics

Reuters
·
Nov 12, 2025

Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment

Reuters
·
Nov 06, 2025

Avenue Therapeutics Inc - Baergic Bio Shareholders to Receive $0.3 Mln Upfront

THOMSON REUTERS
·
Nov 06, 2025

BRIEF-Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Reuters
·
Oct 21, 2025

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

TIPRANKS
·
Oct 21, 2025